Carcinogenic potential of ovulatory genotoxicity

Biology of Reproduction

Volumn 73, Issue 4, 2005, Pages 586-590

  Murdoch, William J ^a  

^a UNIVERSITY OF WYOMING   (United States)

Author keywords

Epithelial ovarian cancer; Ovulation

Indexed keywords

ALPHA TOCOPHEROL; ORAL CONTRACEPTIVE AGENT;

CANCER PREVENTION; CANCER RISK; CARCINOGENICITY; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; DNA DAMAGE; EXCISION REPAIR; FEMALE; GENOTOXICITY; HUMAN; LACTATION; METAPLASIA; METASTASIS; NONHUMAN; OOCYTE; OVARY ADENOCARCINOMA; OVARY FOLLICLE; OVULATION; OXIDATIVE STRESS; PREGNANCY; PRIORITY JOURNAL; SHORT SURVEY;

ADENOCARCINOMA; ANIMALS; CONTRACEPTIVE AGENTS, FEMALE; DNA DAMAGE; EPITHELIAL CELLS; FEMALE; HUMANS; LACTATION; OVARIAN NEOPLASMS; OVULATION; OXIDATIVE STRESS; PREGNANCY; PROGESTERONE; VITAMIN E;

EID: 25144479318     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod.105.042622     Document Type: Short Survey

References (103)

1. Byskov AG. Differentiation of mammalian embryonic gonad. Physiol Rev 1986; 66:71-117.
2. Murdoch WJ, McDonnel AC. Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction 2002; 123:743-750.
3. Hamilton TC. Ovarian cancer, biology. Curr Probl Cancer 1992; 16:5-57.
4. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971; 2:163.
5. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, Schlesselman JJ. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000; 11:111-117.
6. Behrman HR, Kodaman PH, Preston SL, Gao S. Oxidative stress and the ovary. J Soc Gynecol Investig 2001; 8:S40-S42.
7. Auersperg N, Wong AST, Choi KC, Kang SK, Leung PCK. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22:255-288.
8. Yang WL, Godwin AK, Xu XX. Tumor necrosis factor-α-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk. Cancer Res 2004; 64:1534-1540.
9. Murdoch WJ. Ovarian surface epithelium during ovulatory and anovulatory ovine estrous cycles. Anat Rec 1994; 240:322-326.
10. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001; 38:87-95.
11. Webb PM, Purdie DM, Grover S, Jordan S, Dick ML, Green AC. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 2004; 92:232-239.
12. Nahhas WA. Ovarian cancer. Current outlook on this deadly disease. Postgrad Med 1997; 102:112-120.
13. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001; 127:73-79.
14. Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and future. Int J Biol Markers 1998; 13:179-187.
15. DePriest PD, DeSimone CP. Ultrasound screening for the early detection of ovarian cancer. J Clin Oncol 2003; 21(Suppl 10):194-199.
16. Ozols RF. Update on the management of ovarian cancer. Cancer J 2002; 8:S22-S30.
17. Risch HA. Oral-contraceptive use, anovulatory action, and risk of epithelial ovarian cancer. Epidemiology 2000; 11:614-615.
18. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002; 94:32-38.
19. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004; 83:783-795.
20. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. "Incessant ovulation" and ovarian cancer. Lancet 1979; 2:170-173.
21. Hildreth NG, Kelsey JL, LiVolsi VA, Fischer DB, Holford TR, Mostow ED, Schwartz PE, White C. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1981; 114:398-405.
22. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983; 117:128-139.
23. La Vecchia C, Franceschi S, Gallus G, Decarli A, Libertati A, Tognoni G. Incessant ovulation and ovarian cancer: a critical approach. Int J Epidemiol 1983; 12:161-164.
24. Mori M, Harabuchi I, Miyake H, Casagrande JT, Henderson BE, Ross RK. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol 1988; 128:771-777.
25. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Am J Epidemiol 1992; 136:1212-1220.
26. Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer. Int J Cancer 2003; 104:228-232.
27. Heller DS, Murphy P, Westhoff C. Are germinal inclusion cysts markers of ovulation? Gynecol Oncol 2005; 96:496-499.
28. Tung KH, Wilkens LR, Wu AH, McDuffie K, Nomura AM, Kolonel LN, Terada KY, Goodman MT. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol 2005; 161:321-329.
29. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancer in white women. Am J Epidemiol 1992; 136:1184-1203.
30. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771-776.
31. Nieto JJ, Crow J, Sundaresan M, Constantinovici N, Perrett CW, MacLean AB, Hardiman PJ. Ovarian epithelial dysplasia in relation to ovulation induction and nulliparity. Gynecol Oncol 2001; 82:344-349.
32. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995; 346:995-1000.
33. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997; 67:1005-1012.
34. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998; 147:1038-1042.
35. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 1999; 71:853-859.
36. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. Cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol Surv 2004; 59:657-659.
37. Shoham Z. Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertil Steril 1994; 62:433-448.
38. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217-224.
39. Glud E, Kjaer SK, Troisi R, Brinton LA. Fertility drugs and ovarian cancer. Epidemiol Rev 1998; 20:237-257.
40. Clow OL, Hurst PR, Fleming JS. Changes in the mouse ovarian surface epithelium with age and ovulation number. Mol Cell Endocrinol 2002; 191:105-111.
41. Tan OL, Hurst PR, Fleming JS. Location of inclusion cysts in mouse ovaries in relation to age, pregnancy, and total ovulation number: implications for ovarian cancer? J Pathol 2005; 205:483-490.
42. Celik C, Gezginc K, Aktan M, Acar A, Yaman ST Gungor S, Akyurek C. Effects of ovulation induction on ovarian morphology: an animal study. Int J Gynecol Cancer 2004; 14:600-606.
43. Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klein-Szanto A, Hamilton TC, Patriotis C. Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res 2004; 64:8177-8183.
44. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect 1978; 73:35-51.
45. Damjanov I. Ovarian tumours in laboratory and domestic animals. Curr Top Pathol 1989; 78:1-10.
46. Rodriguez-Burford C, Barnes MN, Berry W, Partridge EE, Grizzle WE. Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention. Gynecol Oncol 2001; 81:373-379.
47. Barnes MN, Berry WD, Straughn JM, Kirby TO, Leath CA, Huh WK, Grizzle WE, Partridge EE. A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. Gynecol Oncol 2002; 87:57-63.
48. Collins AR. Oxidative DNA damage, antioxidants, and cancer. Bioessays 1999; 21:238-246.
49. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000; 21:361-370.
50. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003; 17:1195-1214.
51. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Molec Cell Biochem 2004; 266:37-56.
52. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol 2002; 282:C227-C241.
53. Murdoch WJ, Nix KJ, Dunn TG. Dynamics of ovarian blood supply to periovulatory follicles of the ewe. Biol Reprod 1983; 28:1001-1006.
54. Cavender JL, Murdoch WJ. Morphological studies of the microcirculatory system of periovulatory ovine follicles. Biol Reprod 1988; 39:989-997.
55. Murdoch WJ. Programmed cell death in preovulatory ovine follicles. Biol Reprod 1995; 53:8-12.
56. Murdoch WJ, Townsend RS, McDonnel AC. Ovulation-induced DNA damage in ovarian surface epithelial cells of ewes: prospective regulatory mechanisms of repair/survival and apoptosis. Biol Reprod 2001; 65:1417-1424.
57. Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med 2004; 229:553-559.
58. Murdoch WJ, Van Kirk EA, Alexander BM. DNA damages in ovarian surface epithelial cells of ovulatory hens. Exp Biol Med 2005; 230:429-433.
59. Grollman AP, Moriya M. Mutagenesis by 8-oxoguanine: an enemy within. Trends Genet 1993; 9:246-249.
60. Cunningham RP. DNA repair: caretakers of the genome. Curr Biol 1997; 7:R576-R579.
61. Fortini P, Pascucci B, Parlanti E, D'Errico M, Simonelli V, Dogliotti E. 8-Oxoguanine DNA damage: at the crossroad of alternative repair pathways. Mutat Res 2003; 531:127-139.
62. Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Int J Oncol 2000; 16:567-576.
63. Cvetkovic D. Early events in ovarian oncogenesis. Reprod Biol Endocrinol 2003; 1:68.
64. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19:3-10.
65. Murdoch WJ. Metaplastic potential of p53 downregulation in ovarian surface epithelial cells affected by ovulation. Cancer Lett 2003; 191:75-81.
66. Webb PM, Green A, Cummings MC, Purdie DM, Walsh MD, Chenevix-Trench G. Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1998; 90:1729-1734.
67. Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 1992; 84:592-601.
68. Roby KF, Taylor CC, Sweetwood JS, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21:585-591.
69. Dianov G, Bischoff C, Piotrowski J, Bohr VA. Repair pathways for processing of 8-oxoguanine in DNA by mammalian cell extracts. J Biol Chem 1998; 273:33811-33816.
70. Murdoch WJ, Van Kirk EA. Steroid hormonal regulation of proliferative, p53 tumor suppressor, and apoptotic responses of sheep ovarian surface epithelial cells. Mol Cell Endocrinol 2002; 186:61-67.
71. Murdoch WJ. Perturbation of sheep ovarian surface epithelial cells by ovulation: evidence for roles of progesterone and poly(ADP-ribose) polymerase in the restoration of DNA integrity. J Endocrinol 1998; 156:503-508.
72. Lindahl T, Wood RD. Quality control by DNA repair. Science 1999; 286:1897-1905.
73. Wright JW, Toth-Fejel S, Stouffer RL, Rodland KD. Proliferation of rhesus ovarian surface epithelial cells in culture: lack of mitogenic response to steroid or gonadotropic hormones. Endocrinology 2002; 143:2198-2207.
74. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, Dodge R, Hughes CL. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Invest 1998; 5:271-276.
75. Rodriguez G. New insights regarding pharmacologic approaches for ovarian cancer prevention. Hematol Oncol Clin N Am 2003; 17:1007-1020.
76. Ghahremani M, Foghi A, Dorrington JH. Etiology of ovarian cancer: a proposed mechanism. Med Hypotheses 1999; 52:23-26.
77. Nugent D, Newton H, Gallivan L, Gosden RG. Protective effect of vitamin E on ischaemia-reperfusion injury in ovarian grafts. J Reprod Fertil 1998; 114:341-346.
78. Morrissey PA, Sheehy PJA. Optimal nutrition: vitamin E. Proc Nutr Soc 1999; 58:459-468.
79. Herrera E, Barbas C. Vitamin E: action, metabolism and perspectives. J Physiol Biochem 2001; 57:43-56.
80. Azzi A, Ricciarelli R, Zingg JM. Non-antioxidant molecular functions of alpha-tocopherol (vitamin E). FEBS Lett 2002; 519:8-10.
81. Claycombe KJ, Meydani SN. Vitamin E and genome stability. Mutat Res 2001; 475:37-44.
82. Kline K, Yu W, Sanders BG. Vitamin E: mechanisms of action as tumor cell growth inhibitors. J Nutr 2001; 131:161S-163S.
83. Ricciarelli R, Zingg JM, Azzi A. Vitamin E: protective role of a Janus molecule. FASEB J 2001; 15:2314-2325.
84. Neuzil J, Kagedal K, Andera L, Weber C, Brunk UT. Vitamin E analogs: a new class of multiple action agents with anti-neoplastic and anti-atherogenic activity. Apoptosis 2002; 7:179-187.
85. Fairfield KM, Hankinson SE, Rosner BA, Hunter DJ, Colditz GA, Willett WC. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids. Cancer 2001; 92:2318-2326.
86. McCann SE, Moysich KB, Mettlin C. Intakes of selected nutrients and food groups and risk of ovarian cancer. Nutr Cancer 2001; 39:19-28.
87. Tamini RM, Lagiou P, Adami HO, Trichopoulos D. Prospects for chemoprevention of cancer. J Intern Med 2002; 251:286-300.
88. Ames BN, Wakimoto P. Are vitamins and mineral deficiencies a major cancer risk? Nat Rev Cancer 2002; 2:694-704.
89. Senthil K, Aranganathan S, Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta 2004; 339:27-32.
90. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 1998; 25:281-304.
91. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90:1774-1786.
92. Konishi I, Kuroda H, Mandai M. Gonadotropins and development of ovarian cancer. Oncol Suppl 1999; 57(2):45-48.
93. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003; 1:73.
94. Cunat S, Hoffman P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol 2004; 94:25-32.
95. Wang PH, Chang C. Androgens and ovarian cancers. Eur J Gynaecol Oncol 2004; 25:157-163.
96. Nash MA, Ferrandia G, Gordinier M, Loercher A, Freedman RS. The role of cytokines in both normal and malignant ovary. Endocr Relat Cancer 1999; 6:93-107.
97. Grundker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 2003; 1:65.
98. Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int J Oncol 1998; 12:569-576.
99. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Molec Pathol 2002; 55:348-359.
100. Scott JS. How to induce ovarian cancer: and how not to. Br Med J 1984; 289:781-782.
101. Bristow RE, Kaplan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996; 66:499-507.
102. Siskind V, Green A, Bain C, Purdie D. Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 2000; 11:106-110.
103. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF Berchuck A. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control 2002; 13:807-811.